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Abstract 
 
 
Project description:  Company name - GlaxoSmithKline 
The main aim of this project is to discuss and analyse the company’s diversification 
strategy into generics. 
GlaxoSmithKline is one of the largest research-based pharmaceuticals and health care 
companies with the mission of improving the quality of human life by enabling people to 
do more feel better and live longer. The focus of the company lies in three different 
strategic areas such as delivering sustainable growth, reduce risk and improve their long-
term financial performance.1 
 By  
• Growing a diversified global business 
• Delivering more products of value 
• Simplifying the operating model2 
The company entered into branded generics through an alliance with South Africa's 
Aspen Pharm care Holdings, a major supplier of branded and generic pharmaceutical 
drugs. Due to this significant shift from patented drugs to branded generic drugs for 
emerging markets, it forms the basis of our project to look into the challenges and 
opportunities that GlaxoSmithKline would foresee in its change of strategy. 
PROBLEM FORMULATION:     How has branding strategy helped GSK in the shift 
from patented drugs to generic drugs? 
• How has brand positioning been useful to GSK? 
                                                 
1  http://www.gsk.com/responsibility/downloads/GSK-CR-2011-Report.pdf#changing-incentives 
[Accessed July 29, 2012]. 
 
2  GlaxoSmithKline Plc, 2012a. GSK: Our Company. GlaxoSmithKline Plc. [online] Available at: 
http://www.gsk.com/about/company.htm [Accessed July 29, 2012]. 
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• How has GlaxoSmithKline been affected by the transformation from patented 
drugs to branded generic drug through branding strategy? 
 
 
Introduction 
 
 
We are living in the society in which Pharmaceutical companies are becoming highly 
recognized today by adding their names to generic drugs. 
Those companies get in fusion or joint themselves with no brand companies or smalls 
companies to get through the market all over the world. These strategies enable them to 
get through without even knowing the market. In order to understand this strategy, it is 
important to remember why generic brands are able to offer products at a low cost in the 
first place. It is not because associating a name adds to the expense; it is all of the other 
marketing and advertising that go along with it. Pharmaceutical companies can spend 
millions of dollars every year promoting their brands – which ends up getting passed 
along to consumers and their wallets. But simply putting a company name on a drug 
without all of the promotional material can go a long way towards increasing consumer 
confidence and company revenue. 
The intent of this project is to  discover how GSK have employed branding strategy even 
to generic drugs and have succeed in gaining customer trust, loyalty and satisfaction. 
Also, we will look into how the change of GlaxoSmithKline from patented drugs to 
generic drugs affected the company. 
 
 
 
 
History of GlaxoSmithKline 
GlaxoSmithKline has had a long and established history particularly with its consumer 
healthcare products like Panadol, Ribena, Horlicks and Eno. GSK brands are common 
household names and can be found in every kitchen and medicine cabinet. 
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Although the corporate entity GlaxoSmithKline is only ten years old, it traces its roots 
back to the 1715 establishment of the Plough Court Pharmacy in London, England. 
During the next 284 years John K. Smith’s drugstore (established in 1830) and Joseph 
Nathan’s Glaxo dried milk company (established in 1906) would undergo many 
acquisitions, mergers, and name changes, including the integration of the original Plough 
Court Pharmacy. On December 6, 1999 Glaxo Wellcome and SmithKline Beecham 
merged to form the corporation that exits today.  
It is one of the top five pharmaceutical firms in the world, GlaxoSmithKline products 
spans the globe with sales in over 150 countries. Although the majority of their sales are 
in the United States and Europe, the rest of the world accounts for 26% of 2008′s total 
sales. Their products are separated into two categories: pharmaceuticals and consumer 
health care. Pharmaceuticals can then be broken down into eight focus areas: respiratory, 
central nervous system, metabolic, cardiovascular and urogenital, anti-viral, anti-
bacterial, oncology and emesis, and vaccines. Common examples include Flonase, Paxil, 
and Valtrex, and vaccines for influenza, hepatitis B, and poliovirus. The consumer health 
care section also includes a broad range of products such as over the counter medication, 
dental health products, and nutritional drinks. Examples of these brands include Aqua 
fresh, Abreva, Nicotine and Tums. 
 GlaxoSmithKline (GSK) is also working on the production of the H1N1 influenza 
vaccine, global consumer base, and diversity of products. In addition, they have a clear 
business strategy and a commitment to aiding those in the lower demographic. Its wide 
product range covers every aspect of healthcare from vaccines and over-the counter 
(OTC) medication to nutritional beverages, oral care and pharmaceuticals. 
GSK has set up a comprehensive distribution system and specialist dealership scheme 
involving wholesalers, ensuring that the general public has constant access to all products 
all the time. The brand has penetrated the local market and has guaranteed that its 
products are highly visible and contribute to people's health. 
GSK's Global Manufacturing & Supply division is a pioneer of the Good Manufacturing 
Practices (GMP) system. GMP regulations are based on the World Health Organisation's 
Code of Requirements, which the global Drug Control agency in turn bases its guidelines 
upon. 
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With its dynamic sales force and diligent management team, GSK is forging ahead with 
the GSK philosophy of making people do more, feel better and live longer ensuring GSK 
products are the preferred choice always. 
The commercial development of GlaxoSmithKline is more focus on the business 
development department which identifies and evaluates the various outlets, including the 
acquisition and licensing of new products and services to develop and diversify the 
company's portfolio. However, the company has growth through expansion for the last 
years. 
 
 
Company profile 
This section aims to contribute to the better understanding of the rational functioning and 
effectiveness of this company .The company profile is to analyse GSK large 
Pharmaceutical Corporation and its involvement into the generic drugs markets. 
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with 
a powerful combination of skills and resources that provides a platform for delivering 
strong growth in today's rapidly changing healthcare environment. GSK also has 
leadership in four major therapeutic areas - anti-infective, central nervous system (CNS), 
respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area 
of vaccines and has a growing portfolio of oncology products. 
1-  
The company manufactures and supply system of GSK operates as a single global 
network. The company has more than 1 87 manufacturing sites and employ around 
140.000employees in production. It has 2 types of manufacturing sites: there is a primary 
manufacturing site located in the UK, Ireland, the USA, Singapore and Australia. The 
secondary manufacturing sites convert the active compounds into finished products, there 
are 15 of these sites in Europe, 6 of them in north America , 5 in Latin America,5 in the 
middle east Africa, 15 in the Asia ,pacific ,Australia region,4 in china and 2 in Japan. 
Vaccine manufacturing is primarily located at two sites in Belgium. 
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GSK has various co-marketing and co- promotion agreement with other pharmaceutical 
companies and specially the generics drug companies. 
In 2003 GSK held the second position in pharmaceutical market ,with a world market 
share of 9.6% .This is after Plizer, which had a share of 10.3% .GSK is a leader in the 
four  therapeutic areas in vaccines. 
Worldwide it had a market share of over 20% for respiratory treatments, share systems 
approximately 13%for anti-infective and close to 10% of the central nervous systems 
drugs. 
GSK generic drugs manufacturing are seeking to bring generic version of manufacturing  
and most important products of the company to the market before patent expire .Generic 
market of GSK competing with paxil and augmentin company, launched in 2002 and 
2003 and had considerable adverse impact on its sales and profits.3 
 
The company has two divisions:  
Business profile of GSK: 
GSK is one of the world’s largest research based pharmaceutical company that discover, 
develop, manufacturing and market human health products. 
It is an innovative company that produces branded and generic drugs in the world, which 
it has developed itself. 
GSK policies: 
GSK policies in the markets is to improve the quality of human life by enabling people to 
do more and feel  better and live longer , its key values are performance with integrity, 
entrepreneurial spiral focus on innovation in the sense of urgency and the passion for 
achievement. 
GSK policies markets are divided in many steps such as: 
-Employee practices: GSK will treat employees fairly, encourage world force divert and 
offer save and healthy working conditions. 
-Leadership and vacancy: GSK will establish its own standards in the generic drugs 
markets and will seek to influence the others. 
                                                 
3 GSK annual report 2003 p.34 
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-Access to the medicine: GSK will continue to create medicines for developing countries, 
find suitable ways to provide access to medicines and seek partnerships to support it. 
-Communities investment: GSK will invest in health and education program in 
partnerships for health in deeper in Europe and developing countries. 
Research and innovation: GSK will ensure that its products are well evaluated and tested 
on safety, effectiveness and quality. 
 
Mission and vision 
 GlaxoSmithKline have a challenging and inspiring mission to improve the quality of 
human life by enabling people to do more, feel better and live longer. The key behaviours 
which distinguish their successful people are innovative thinking, engaging and 
developing others, leading people and achieving excellence. 
GSK carry out their business with the enthusiasm of entrepreneurs, excited by the 
constant search for innovation. They also have a strong culture of performance achieved 
with integrity. GSK is confident of attaining our set goals because our people work bring 
to the workplace an attitude of passion and positive energy. 
 
Motivation 
The inspiration behind this project to investigate the fact that GlaxoSmithKline, one of 
the largest research-based pharmaceuticals and health care companies is trying to 
improve the quality of human life by enabling people to do more on health care, so they 
feel better and live longer. This mission has led them to a world-leading position in 
developing new medicines, vaccines and consumer healthcare products that are used by 
millions of poor and rich people around the world.  
GlaxoSmithKline shift from patented drugs to the branded generics continues to drive 
very successful in the world despite the competition. For instance, GlaxoSmithKline took 
a bold step on 23 July 2008 and entered into branded generics via an alliance with South 
Africa's Aspen Pharmacare Holdings, a major supplier of branded and generic 
pharmaceutical drugs all over the world. 
Before that, the company was known as a normal brand company. Due to this significant 
shift from patented drugs to branded generic drugs for emerging markets, it forms the 
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basis of our project to look into the challenges and opportunities that GlaxoSmithKline 
would foresee in its change of strategy.   
The challenge of improving healthcare and expanding access to more people is great, and 
no single organization can provide all the solutions.  Healthcare companies have a role to 
play, and GlaxoSmithKline want to be a company that makes a difference. 
Based on such concern, we intend to understand the change of GlaxoSmithKline 
Company from patented drugs to generic drugs.  
    
Problem Area 
These private enterprises and the generics drugs markets developed very fast because 
consumers in the emerging global markets often pay out-of-pocket for medicine and 
cannot afford the expensive brands, therefore pharmaceutical leader GlaxoSmithKline is 
by-passing the American market and heading straight to Europe, Asia, and Latin America 
where they can offer lower-priced, lower-profiled drugs to consumers who are not biased 
against generic branding. The generics drugs markets are growing very fast on consumer 
base on the emerging markets in the world because of the fact that in many countries, 
people are paying out of their pocket for their medicines and often cannot afford 
expensive brand name drugs. .The change of GlaxoSmithKline can bring a fear of 
counterfeit drugs or low quality medicines. Therefore more and more companies are 
facing a large challenge by growing a diversified global business in order to strength their 
core competitiveness on the market. We will use the qualitative data to analyze and  to  
understand  the shifting process into delivering more products of value and simplifying of 
the operating model. 
 
Thus our problem formulation:    
How has branding strategy helped GlaxoSmithKline in the shift from patented drugs to 
branded generic drugs? 
    
Working questions: 
• How has brand positioning been useful to GSK? 
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• How has GlaxoSmithKline been affected by the transformation from 
patented drugs to branded generic drug through branding strategy? 
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Project Design 
 
   
In order for the reader to know what is important to focus on in the project, we will 
provide an account of the project design. The following are the 6 main chapters of this 
report. 
 Introduction 
 Methodology 
 Theory 
 Analysis 
 Conclusions 
 Afterthoughts/ limitations 
 
The introductory section consists of introduction, Motivation and problem area, problem 
formulation and working questions as well as the project design. 
 
Next is the methodology section, which will accounts for the methodological choices and 
considerations in this project. In addition, are the epistemological and the ontological 
positions. The type of data will also be included, which consists of books websites and 
other sources. 
 
Follow by the theory section is made up the chosen theory and how it will be useful and 
its delimitations in this project. 
Preceded by the analytical section, where we can find the two main working questions 
and the empirical materials gathered for each question. The initial section will displace 
the first working question “How has brand positioning been useful to GSK? “ 
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By using the strategy of branding decisions, we will analyse  how GlaxoSmithKline 
branding positioning is designed to enhance the identity of the generic products through 
the use of the unique brand names, symbols and other distinctive measures. 
The next working question “How has GlaxoSmithKline been affected by the 
transformation from patented drugs to branded generic drug through branding 
strategy? “ 
And in this part, our analytical focus will be on both the positive and the negative 
outcomes of GlaxoSmithKline’s shifting.  
Ultimately, the report ends with the conclusion and afterthoughts where we will further 
elaborate on our chosen approaches. 
 
Philosophy of Social Science 
Analysing the proposed topic, it is important to consider and reflect upon the methods 
and theory that are to be used carefully since those will be crucial for the course of the 
project and determine our ontology as well as epistemology. Therefore, the following 
chapter will be used to present our methodological decisions as well as the data collecting 
that we base our analysis on.  
 
 
 
 
Methodological considerations 
 
 
The purpose of this chapter is to look into the methodology of our project and clearly 
state the employed scientific approaches in this project report; by doing so, we will 
explain how we will analyse the research questions including the various methodological 
choices made during the writing process.  Hence, we will account for our overall 
methodological approaches. 
 
To help people use discourse more effectively, we must first understand its normal uses. 
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The purpose of this Unit is to provide an introduction to the topic of written discourse 
analysis 
Discourse Analysis will, not provide absolute answers to a specific problem, but enable 
us to understand the conditions behind a specific "problem" and make us realize that the 
essence of that "problem", and its resolution, lie in its assumptions; the very assumptions 
that enable the existence of that "problem" 
By enabling us to make this assumption explicit, Discourse Analysis aims at allowing us 
to view the "problem" from a higher stance and to gain a comprehensive view of the 
"problem" in relation to that "problem" 
Discourse Analysis research/findings depends on the force and logic of one's arguments. 
Even the best constructed arguments are subject to their own deconstructive reading and 
counter-interpretations. 4 
 
We are doing discourse analysis of how branding strategy has help GSK in shifting from 
patented drug to branded drugs. 
Discourse analysis is a form of qualitative content analysis and was first outlined by 
Foucault5 . Its purpose is to look inside the text for meaning, and relationship between 
texts and with all discourse that exists simultaneously and has come before. 
By using discourses, we will qualitatively analyse the data gathered from the webpage of 
GSK to determine how truth and meaning are established in a historically specific time 
and place, thus, the reason for employing qualitative research method, in order to get in-
depth with our problem formulation. Foucault’s method of describing discursive 
formations is primarily through historical and archival research, with special attention to 
the documents that give voice to the marginalized people and ideas of that particular 
moment in history. 
 
                                                 
4 Budd, John and Douglas Raber. (1996) "Discourse Analysis: Method and Application in the Study of 
Information."Information Processing & Management32, p. 217-226 
 
5  Foucault, M. (1969) The Archaeology of Knowledge, London: Tavistock 
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We will employ a deductive reasoning which works from the more general approach to 
the more specific approach. At the same time, conclusion follows logically from 
premises. 
 
 
 
 
Figure 1 
 
The research strategy for this project is based on a deductive analytical strategy which is 
explained as working from the more general to the more specific. We begin with thinking 
up our branding theory about GSK branding strategy then we narrowed that down into 
more specific hypotheses that we can test. We will narrow down even further when we 
collect data to address the hypotheses. This ultimately leads us to be able to test the 
hypotheses with specific data -- a confirmation (or not) of our original theory. 
 
 
With a deductive approach we will employ qualitative research method. This is so, 
because we regard this as being the most efficient in our case, as we are interested in 
going in depth with the addressed issues and thoroughly analyse the process of the 
shifting through branding strategy. However in order to increase the validity and 
relevance of our study, we intend to obtain empirical data consisting of articles, online 
databases, research reports, books and finally established theories. 
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Epistemology & Ontology 
 
 
As stated above, we are doing Discourse analysis which is part of the Constructivist (or 
Social Constructivist) approach within the social sciences. It assumes that basic 
assumptions with regard to being, self and the world are constructed by individuals living 
in a historical and cultural context which is produced and reproduced by their speech 
acts. 
Therefore, based on the project's rather qualitative nature as discussed in the previous 
section, we adhere to a constructivist ontological position as we base our research on the 
argument that the existence of reality is constructed rather than simply discovered.6  The 
idea of external world is dependent on the individual mind. So through this view, reality 
is considered as real only to the extent that individuals think of it as real.7  
Therefore, social phenomena and social reality is following this view, constructed 
through the human mind leading to a state of as many realities as there are people. 
 
With that, we have decided to take  an interpretivist epistemological stance which 
acknowledges the fact that , we as researchers, come from different background with 
different cultures and set of values and that it is impossible to be completely objective.8  
Also, after the collection of our data, we will not be able to get a direct understanding of 
the data until we apply our interpretation of the gathered data.  Although we are aware 
that one of the weaknesses of this type of content analysis is that it is always dependent 
on the analyst’s interpretation, and is thus the product of that person’s bias, filters, or 
prejudices. With this concern we intend to be constantly reflexive of our actions and take 
stock of our involvement. 
                                                 
6  Blaikie, N. (2007) Approaches to social enquiry, p. 19) 
7  Ibid., p. 16) 
8    Bryman, A. (2008) Social Research Methods (3rd ed.) New York: Oxford University Press, pp.593 
16 
 
Doing a qualitative discourse  analysis of our data will aid in revealing and understanding  
the social construction of our social phenomena in our project, however, we are aware of 
constructivist views do not consider reality  that may exist externally to individuals.9  
 
 
Methods 
 
In this section, we will discuss the advantages and limitations of the research methods 
that are being utilized in this project. This includes: the deductive analytical strategy, 
qualitative research methods and analysing of gathered secondary data 
 
Qualitative research Methods 
This scientific approach will aid in obtaining understanding through description and 
explanation of the empirical data. The reason for this approach is that it will provide more 
in-depth and comprehensive data since the nature of the problem is more complex to 
answer by a yes or no hypothesis through questionnaire. With this, we make fewer 
assumptions and this is good for our explanatory research.10 
It also gives the advantage to investigate problems that cannot be quantified, for instance 
individual experiences. Also, for us as researchers, we will gain more detailed and rich 
data in the form of comprehensive written descriptions or visual evidence, such as 
photographs. This type of research looks at context and social meaning and how it affects 
individuals, and in our case, GlaxoSmithKline. 
 
Data 
The materials which will be used to analyse this particular problem in this project will be 
solely primary data due to the nature of the problem. This will make provision for 
comparison of data gathered, as well as benefiting from other researchers in this field 
which for the most part will ensure quality data 
                                                 
9 Bryman, A. (2008) Social Research Methods (3rd ed.) New York: Oxford University Press, pp.20 
10  Uwe, Flick, (2002) An introduction to qualitative research, 2nd ed. London: sage) 
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Generally speaking, primary sources are those data which are unpublished and which the 
researcher has gathered from the people or organization directly, and we are acquiring our 
data from the webpage of GSK and other sources such as books, articles etc. which have 
been previously published. 
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Theory 
 
   
In this theoretical chapter, we will present our opted theories, which will provide the 
basic knowledge necessitated in analysing our empirical data. 
The strategy of branding decision will be applied as the chosen theory. The purpose of 
this is to aid in answering our problem formulation.  
 
Figure 2 
 
As seen in the above figure, the brand strategy decision consists of four categories, which 
are the brand position, the brand name selection, brand sponsorship and brand 
development.  However in this project will only deal more with the brand position. 
Our purpose of choosing this theory is that it relates directly to our problem formulation 
and with this theory we will able to follow closely how GSK has employed branding 
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strategy,  specifically, branding position in their shifting from patented drugs to generic 
drugs.  
 
According to Ghodeswar, Branding signifies to the customers the source of the product, 
and products both to the customers and the producers from competitors who would 
attempt to provide products that appear to be identical. From the customer’s point of 
view, a brand can be defined as the total accumulation of the customer’s experiences and 
is built at all points of contact with the customer.11 
 
Definition of a brand 
Brand is a name, term, sign, symbol or design, or combination of these intended to 
identify the goods or services of one seller or group of sellers and to differentiate them 
from those of competitors.12 
 
Therefore what is brand identity? 
Brand identity is the noticeable elements of a brand, for instance - Trademark color, logo, 
name, and symbol that identify and differentiates a brand in target audience mind. It is a 
crucial means to grow a company’s brand. It is the aggregation of what all that an 
organization does. It is an organization’s mission, personality, promise to the consumers 
and competitive advantages. It includes the thinking, feelings and expectations of the 
target market or consumers. It is a means of identifying and distinguishing an 
organization from another. An organization having unique brand identity have improved 
brand awareness, motivated team of employees who feel proud working in a well branded 
organization, active buyers, and corporate style. 
 Brand identity leads to brand loyalty, brand preference, high credibility, good prices and 
good financial returns. It helps the organization to express to the customers and the target 
market the kind of organization it is. It assures the customers again that you are who you 
say you are. It establishes an immediate connection between the organization and 
                                                 
11  Bhimrao M. Ghodeswar, "Building brand identity in competitive markets: a conceptual model", 
Emerald 17, (2008) 
12  Kotler, P. & Armstrong, G.. (2006) Principles of Marketing, 11th ed.), United State of America, Pearson 
Prentice Hall 
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consumers. Brand identity should be sustainable. It is crucial so that the consumers 
instantly correlate with your product or service. 
 
What is brand personality? 
 Brand personality is the way a brand speaks and behaves. It means assigning human 
personality traits or characteristics to a brand so as to achieve differentiation.13 These 
characteristics signify brand behaviour through both individuals representing the brand 
(i.e. it is employees) as well as through advertising, packaging, etc. When brand image or 
brand identity is expressed in terms of human traits, it is called brand personality. 
Brand personality is therefore the result of all the consumer’s experiences with the brand. 
It is unique and long lasting. 
However, Brand personality must be differentiated from brand image, in sense that, while 
brand image denote the tangible, such as the physical and functional benefits and 
attributes of a brand, brand personality indicates emotional associations of the brand. If 
brand image is comprehensive brand according to consumers’ opinion, brand personality 
is that aspect of comprehensive brand which generates its emotional character and 
associations in consumers’ mind. 
Brand personality develops brand equity. It sets the brand attitude. It is a key input into 
the look and feel of any communication or marketing activity by the brand. It helps in 
gaining thorough knowledge of customers feelings about the brand. Brand personality 
differentiates among brands specifically when they are alike in many attributes. For 
instance - GSK versus ASPEN. Brand personality is used to make the brand strategy 
lively, that is, to implement brand strategy. Brand personality indicates the kind of 
relationship a customer has with the brand. It is a means by which a customer 
communicates his own identity. 
Brand personality not only includes the personality features/characteristics, but also the 
demographic features like age, gender or class and psychographic features. Personality 
traits are what the brand exists for.  
 
                                                 
13  John F. Tanner, Jr., Mary Anne Raymond, v 1.0 Principles of Marketing. Flat World Knowledge 
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From the definitions seen above, it is very important for a company to be well positioned 
both in the market and in the minds of its customers. 
 
 Therefore, what is brand positioning?  
According to Phillip Kotler, brand positioning is how the product is perceived in the 
minds of the customers in relation to competitors brand in the market. He defines 
positioning as “the way the product is defined by consumers on important attributes - the 
place the product occupies in consumers’ minds relative to competing products. 14 
Brand positioning is a continuous communication to consumers via advertising, personal 
experiences with the brand, word of mouth, company web pages etc. 
Branding poses challenging decisions to marketer, and therefore marketers need to 
position their brand clearly in target customer’s mind. The brand can be positioned on 
any of the three levels known as: 
 Attributes, which is the lowest level of the three positions, since it is the least desirable 
level of positioning. It is how companies can differentiate the product itself (Product 
Differentiation), on attributes as “innovation, consistency, durability, reliability or 
reparability”.15 Customers are more concern and interested in what the attribute of the 
product can do for them instead and not the impressive talk about the attribute associated 
with the product. Also, it is very easy for competitors to copy attributes. 
Customers would prefer if a brand can be positioned by associating its name with a 
desirable benefit than attributes. This is where marketers focus on what the product 
works for. 
Lastly is the brand beliefs and values. It is evident that the strongest brands go beyond 
attributes and benefits, but rather they are positioned on strong beliefs and values 
Brand experts Marc Gobe argues that in order to attain successful brands, companies or 
marketer must engage their customers on a deeper level by touching a universal 
emotion.16 
 
                                                 
14  Kotler, P. (2002), Marketing  Management,  Prentice Hall p. 269  
15 Kotler, P. (2002), Marketing  Management,  Prentice Hall p. 360 
16  Joseph Webber, “3M’s Big  Cleanup, “ Business Week,  June 5, 2000, pp.96-98 
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Conclusion 
After the above discovering of positioning strategy, the concept of branding is a crucial 
part of a company’s differentiation. It has become clear that GSK stands for improving 
the quality of human life at reasonable prices. It offers a range of products for the whole 
family which are available in global local pharmacies,  
GSK has been extremely successful because their marketing mixes are consistent with 
their images and thus they are able to maintain their position through consistent 
performance and communication. 
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Analysis 
 
  
In this section, the definition for generic and branded products (in this case, drugs) will 
be accounted for.  As a well as the two working questions in the project, will addressed, 
analysed and answered with the gather data. 
 
Working Question 1: How has brand positioning been useful to GSK? 
Since GSK is relatively large companies and is found in numerous countries, we will 
narrow our focus to the information from their headquarters which is situated in London 
UK. 
According to Sir Andrew Witty, Chief Executive officer of GSK, Pharmaceutical industry 
is very complex and dynamic in nature. Various sorts of unprecedented challenges are 
faced by the industry. There is a constant increase of pressure from healthcare providers, 
regulatory issues and patent expires. These have contributed to an environment that has 
subjected to lower growth and high risk factors.17 GlaxoSmithKline has concentrated 
their business on three primary priorities i.e., growing diversified global business, 
delivering more products of value and simplifying the operating model. Through these 
priorities they aim to deliver sustainable growth, improve long-term financial 
performance and reduce risks and thus adhere to their mission of improving quality of 
human life that enables people to do more, feel better and live longer.18  
 
 
 
 
 
 
                                                 
17 Annual Report: GlaxoSmithKline Plc. 2011 
18 GlaxoSmithKline Plc., 2012b 
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SWOT Analysis:  
 
Strengths:  
• GSK has Strong Sales. 
• Their balance sheet and financial statements is good and comprehensive. 
• Good marketing infrastructure. 
• It has strength in Industry leading R&D team. 
• GSK has an effective implementation and execution of strategic priorities, life 
cycle management strategies and business fundamentals. 
• It also has the ability to reduce on costs. 
 
 
Weaknesses: 
• GSK, has no clear, widely shared goals for the system 
• Lack of sustainable training and management skills 
• It faces difficulties with continuity of care (leading to frequent cases of patients 
lost in system) 
• Raising cost sharing- this is as an expression of inability to cope with cost 
increases 
• The inter-sectorial linkages between health care, public health and social care is 
poor 
• The possibility of Co-marketing agreements  limiting GSK's global presence 
• It also has an unsustainable revenue base 
• The company is geographically and diversely located 
• GSK has a low ability to retain the professionals 
•  The ratio of different competences is unfavourable 
 
 
Opportunities: 
•  GSK possess a strong cash and assets position. 
25 
 
• It is an opportunity for GSK to entry into antibodies and biologics segment of 
market. 
• GSK has the potential to deliver strong growth by R&D team. 
• The effect of generic products sales on sales of the company. 
• It also has the potential to expand business in emerging markets. 
• Positive change in governmental and federal laws that may concerns with the 
healthcare. 
 
Threats: 
 The threat of demographic change and ageing 
 The threat of counterfeit drugs being sold in competition with legitimate products 
 Higher expectations of people  to health system 
 The increasing cost of drug trials and ever higher standards imposed by national 
drug approvals bodies. 
 An increase in the number of safety issues surrounding products 
 The threat of competition from products similar to GSK's in R&D that reaches the 
market close to or before GSK's products. 
 The ecological and public health threats 
 The new economic potential of emergent China, India and competition in diverse 
regional markets. 
 Patent expiry on drugs that generates strong income could be a threat 
 
GSK has capitalized on its strengths and available opportunities over the years and has 
successfully minimized weaknesses and eliminated threats.19 
 
 
 
 
 
 
                                                 
19 Adapted from Annual Report: GlaxoSmithKline Plc. 2011 
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BCG Matrix: 
 
Figure 3 
Source: Adapted from- Annual Report: GlaxoSmithKline Plc. 2011 
 
Cash cows: are units with high market shares in a slow-growing industry. As a leader in a 
mature market, cash cows exhibit a return on assets that is greater than the market growth 
rate. Meaning, they generate more cash than they consume. These units are milked by 
extracting the profits and investing as little as possible. 
 
Dogs: have a low market share and a low growth rate. It does not generate or consume 
large amount of cash but it is a cash trap due to the cash locked up in the less potential 
business. 
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Question marks: it is characterized by rapid growth and therefore consumes high 
amount of cash. However, they have low market shares and do not generate much money, 
but it has the potential to gain higher market shares and become a star and finally a cash 
cow when they market grow slow. 
 
Stars: are units with a high market share in a fast growing industry, with the hope that the 
stars will eventually become cash cows if it is maintain in the category of leadership. 
 
GSK has high relative market share and high market growth rate along with good cash 
flow. This puts GSK under “star” category in BCG matrix. 
GSK has a product portfolio with a significant cash flow position this in turn has spurred 
on a meaningful gearing by GSK management. This puts the company firmly in a star 
performing position. With asset consolidation of $23.5bn USD over three years, the 
company is likely to attain double-digit earnings growth, with mid-digit growth in 2012 
impacted by generic competition.20 
 
Porter’s Five Forces: 
 
• Threat of new entrants: Due to the high costs required to enter the pharmaceutical 
and healthcare industry, the threat of new entrants is quite low. The economies of 
scale for production may not be very significant but there are other barriers to 
entry. It is very timely and costly process to develop new products that requires 
extensive research and development.21  The government and federal laws and 
Food and Drug Administration impose strict rules and standards on the companies 
that can act as a barrier to entry. Patent expiries is a huge barrier for the new 
entrants in this industry, as the patents last about 20 years and thus the products 
are protected by their respective companies. The new firms trying to enter the 
                                                 
20 www.gsk.com ( Available 11/11/2012) 
21  Kasapi, Z., 2011. Management as applied to New Products Penetration in the Competitive Environment 
of Pharmaceutical Industry. Interdisciplinary Journal of Research in Business, 1(10), pp.73–85. [online] 
Available at: http://www.idjrb.com/articlepdf/idjrb10n1p9.pdf (Available:10/10/2012) 
 
 . 
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market could find this very discouraging. The already established firms like GSK 
have constructed strong brand names and loyalty with its customers thus making 
it difficult for new firms to build up a competitive brand name.  
 
Threat of substitutes: GSK faces a huge threat from generic brand medication- often 
seen as the main substitute of the products produced by pharmaceutical companies. 
Complementary Alternative Medicines (CAM) is another substitute of GSK products. 
The generics, CAM and brand names are the same product delivered to the customers, the 
only difference being name and price.22  
 
Bargaining power of buyers: Buyers do not pose significant threat on GSK, as the 
company spends most of its R&D to develop new patent products. The major consumers 
of products are doctors, pharmacists, patients, hospitals and other healthcare facilities. 
Considering the number of buyers in the market, the power of buyers is relatively small.23 
 
Bargaining power of suppliers: The main suppliers for GSK are labour, raw material 
providers, patient’s in clinical trials, study staff, investigators and other ranging from 
production, marketing to distribution.24 The suppliers hold immense power and can 
impose a considerable threat to the company by withholding supplies or reducing the 
quality of supplies and thus can have a major effect on GSK. 
 
Rivalry among competitors: Pharmaceutical industry is very aggressive and dynamic. 
There is the constant struggle for market share within the dynamics of the industry based 
on innovation and new patent products. The rivalry is such in this environment where 
                                                 
22  Kasapi, Z., 2011. Management as applied to New Products Penetration in the Competitive Environment 
of Pharmaceutical Industry. Interdisciplinary Journal of Research in Business, 1(10), pp.73–85. [online] 
Available at: http://www.idjrb.com/articlepdf/idjrb10n1p9.pdf. 
 
23  Otieno, C.J., 2006. Analysis of Strategic Alliance Deals in the Global CNS Industry. Simon Fraser 
University Library, (1). [online] Available at: 
https://el.trc.gov.om/htmlroot/ENGG/tcolon/e_references/NDLTD/Industrial Biotechnology 
Engineering/Thesis/Analysis of strategic alliance deals in20the global CNS industry.pdf. 
 
24  Ibid 
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only the strongest would survive.25 GSK has used foresight and planning to position them 
for success in the long term. 
 
Sub- conclusion: GSK should reduce risks and threats by broadening its range, 
expanding in to new product areas with potential and seizing opportunities across other 
geographic boundaries. It should explore the segment of vaccines, biopharmaceuticals 
and consumer healthcare that has definite potential and thus increase its sales growth. It 
should focus on the geographical potential of its business in emerging markets and 
economies. GSK should also focus on its R&D team- its training and development and 
new scientific discoveries to ensure constant delivery of current products and new 
products in future. The global restructuring program and the slight change in business 
model that can open channels of diversification and business growth could be expected to 
be more profitable in the long-term. It should concentrate on Return on Investment and 
reducing its working capital to sustain its current position and emerge as a market leader 
in future. 
 
Analytical Section: 
In this section it necessary to give an account of the definition of both patented and 
generic drugs. Followed by how successful GSK has positioned itself in the minds of its 
customers even in the shifting from patented drugs to generic drugs. 
Generic Drug and Branded or patented Drug: 
 
Generic drugs  
A generic drug is an identical copy (bioequivalent) of a brand name (or proprietary) drug. 
Generics are exactly the same as their branded counterparts in dosage form, safety, and 
strength, route of administration, quality, performance characteristics and intended use. 
The notable difference between the two is the price.  
                                                 
25   Kasapi, Z., 2011. Management as applied to New Products Penetration in the Competitive Environment 
of Pharmaceutical Industry. Interdisciplinary Journal of Research in Business, 1(10), pp.73–85. [online] 
Available at: http://www.idjrb.com/articlepdf/idjrb10n1p9.pdf. 
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Generic drug manufacturers incur fewer costs in creating the generic drug, as they do not 
have to cover the expense of drug discovery, or lengthy safety and efficacy trials. Instead 
generic makers’ reverse-engineer known drug compounds. This means that generic 
manufacturers are able to maintain profitability while offering the drug at a much lower 
cost.  
This is problematic for pharmaceutical companies who argue that generic copying 
reduces their profits and decreases the amount of money they can spend on researching 
and developing new antiretroviral drugs. In order for the proprietary drug makers to 
recoup the money they spent on drug creation, they are granted a ‘patent’ (an intellectual 
property right), which is an exclusive right that prevents others from making, using, 
selling, offering to sell, or importing their drug. The patent typically lasts for twenty 
years.26 
 
Branded/ Patented drugs: 
 
The original manufacturer of a drug receives a patent on the drug and is the only 
manufacturer who can produce and sell the drug during this patent period. Once the 
patent expires, other manufacturers may produce and sell the drug. These manufacturers 
usually sell the drug under its common or generic name. 
Patents are considered to be insurance for inventors, including research-based Pharma 
companies, since drug innovation risk, expense and time for its development. Any new 
drug that was developed came under patent protection.  
 
Kotler believes that nowadays customers do not buy attributes and benefits, they buy 
brands. In making purchase decisions, consumers have more information at their at hand 
than ever before. But rather than serving to inform their decisions, this overloaded 
information from companies confuses customers to the point where the only way they 
can make a purchase decision is based on their own value judgments. The only way 
brands can make connections is therefore by articulating emotional benefits of a product 
                                                 
26 http://www.avert.org/generic.htm (Available 10/12/20012) 
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that connect with a customer’s value judgement. Attributes and benefits are just not 
enough. 
According to Kotler, positioning is “the way the product is defined by consumers on 
important attributes - the place the product occupies in consumers’ minds relative to 
competing products.”27  
Consumers hold a complex set of perceptions, impressions and feelings for a particular 
product that compares with competing products. These perceptions, impressions and 
feelings do not emerge randomly but companies work thoroughly on influencing them in 
order to differentiate from other companies’ products. However, before GKS is able to 
position its product, a target audience must be identified.28  
 
This is the role of market segmentation. After having segmented the market, GSK 
identifies its target group and the differences to competing products. 
 
There are four areas in which GSK can differentiate its products from the competing 
products. That is through: “product, services, personnel and image” (Kotler (2002), p. 
360) 
GSK have differentiated itself through its products, personnel and image. 
Looking at its Product Differentiation, it is built on attributes as “innovation, consistency, 
durability, reliability.”29  
With Personnel Differentiation, GSK aims at training and educating their staffs in order 
to secure high skilled staffs. 
Finally, the Image Differentiation which required that GSK had to work to “establish 
images that differentiate them from competitors.30 Logos and adverts but also 
sponsorships are the main aids to develop a strong and distinct image in the customer's or 
public’s mind. This is quite difficult and complicated task to accomplish, however GSK 
has been very successful in this regard so far. 
 
                                                 
27 Kotler, P. (2002), Marketing  Management,  Prentice Hall p. 269 
28 . Dukta, Allan, Product Positioning Overview,article on www.marketingpower.com 
29 Kotler, P. (2002), Marketing  Management,  Prentice Hall p. 360 
30 Kotler, P. (2002), Marketing  Management,  Prentice Hall p. 363 
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So it can be stated that, branding is a process, a total experience a customer has with the 
company, its product or service 
It is the experience customers have with the company, rather than what the companies 
provide. Most definitions of brand rely on what the company does, rather than the 
customer’s experience.  
 
 
Working Question 2 
How has GlaxoSmithKline been affected by the transformation from patented drugs to 
branded generic drug? 
 
Positives changes: 
The world of pharmaceutical industry and more specifiable GlaxoSmithKline underwent 
true an important transformation during the change into brand generic products. To 
survive under the new market conditions, the company had to refocus their competitive 
strategies towards increasing productive efficiency and reinforcing research and 
development activities. The results suggest that pure technical efficiency change and the 
scale change of the technology explain most of the productivity growth observed during 
this period. The contribution of technical change to productivity growth is negligible.  
.One consequence, the opportunity to develop a new market, less expensive drug 
products, is already having a positive impact on patient’s cases and generic GSK bottom 
lines. Others, such as the role biosimilars will play in the future, remain to be seen. 
Because generic equivalents are less expensive alternatives, they play a huge role in 
lowering health care costs. 
 The average retail price of a generic drug is lower than the retail price of a brand name 
drug. The generic market makes up a much smaller portion of drug spending, despite the 
fact that generic medications outnumber branded products by future. 
 The United States has one of the world’s largest generic drug markets, dispensing almost 
all prescriptions in the retail setting as generics and GKS operating in all over the 
country. This proportion is expected to rise higher by becoming years, driven in part by 
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the patent face and also by strategies that third party payers, such as Medicare and private 
health plans,  GSK have put into place to encourage generic use. 
GSK brand generic is much more in poor countries or development. To improve health in 
developing countries, it is thus necessary that all actors of society, both nationally and 
internationally, that is for example governments, international institutions, the private 
sector and civil society as a whole, working side by side, creating new forms of 
partnership. 
 This is why GSK has lent its support to the commitment of the United Nations Secretary-
General Kofi Annan for a global mobilization of new resources. GSK has new method to 
sell, and to gain steps in these poor areas and target more customers. 
 GlaxoSmithKline is visibly committed to its responsibilities by adopting an approach 
that is innovative, responsible and sustainable especially to cope with these challenges. 
While the industry has neither the mandate nor the expertise nor the resources to provide 
health care unilaterally, there are three key areas in which GSK has used to contribute and 
to achieve tangible and lasting results: 
2- Continued investment in research and development on diseases that particularly 
affect poor countries. GSK is conducting research and development efforts, both 
in the field of prevention and treatment on the three diseases listed a top priority 
of the World Health who is HIV / AIDS, malaria and tuberculosis. This 
commitment is now long pursued actively and massively. 
3- Offer preferential rates and long-term renewable for the Least Developed 
Countries (LDCs) and those of sub-Saharan Africa currently available drugs and 
they need it most. This policy of preferential tariffs practiced in recent years in the 
field of vaccines. 
4- Play a role in outreach activities for effective health care. GlaxoSmithKline is 
currently involved in partnership projects funded by local industry in 96 countries 
around the world: donations additional commitment of its human resources and 
partnerships at the local level. We are also involved in the largest drug donation 
program in the world through an international partnership to eliminate lymphatic 
filarial. This donation will be maintained until this goal is achieved, which 
corresponds to the distribution of 5 to 6 billion doses of treatment. In the field of 
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HIV, the international subsidiary of GSK has implemented in 1998 a corporate 
foundation whose initial objective is to support the implementation of programs 
of care for people with HIV in the country development. Today, it supports twelve 
care programs underway in seven African countries. 
 
In the past years, the structure of American pharmaceutical industry has changed 
intensely caused by the aging of population, the emerging of bio-pharmaceutical 
technology and fierce global competition.  GlaxoSmithKline is one of the key players in 
the US, include the others players such as: Pfizer, Johnson & Johnson, Merck. 
 
 
Figure 4 
American pharmaceutical companies paid great attention to the evolution of the generics 
drug market due to the free market competition and patent protection of new medicines in 
the US. Since the year of 2000, GSK expenditure has been maintaining an increase, even 
in 2008, impacted by the global financial crisis, GSK expenditure totalled at US $65.2 
billion, up 3.16% of last year.  
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There are 2,900  generics drugs currently in research in US, among which 750 are 
anticancer drugs, 312 drugs are for heart diseases, 150 are diabetes drugs and 109 are 
AIDS drugs, the rest 91 drugs are for the Alzheimer and senile dementia diseases.31 
  
In 2009, the sales growth of drugs in the United States is expected to around 1% ~ 2%. 
The growth of biotechnology, special drugs and generic drugs will be higher than the 
average.  
 
The report focus on the 30 pharmaceutical companies in the United States, including their 
profiles, revenue and profit, as well as their products, market distribution and 
development strategies in which GSK is one of the biggest on sales. 
The development of the company's commitment on these three guidelines should 
contribute to improving health care in developing countries and the GSK image through 
the world. These actions, on-going for some decades, will continue in a sustainable 
manner and concentrated in the therapeutic areas, GSK has make more and one of the 
objectives of GSK is thus contribute to the development of new processes to make these 
medicines available and accessible in developing countries, according to a more holistic 
approach to health care. In light of the global health situation, access to medicines is a 
challenge that the pharmaceutical industry must respond. Legitimacy implies that it 
reaches today offer medicines adapted to the needs of these populations and contributes 
to solving the problem of access to medicines. GSK has created access to medicines in 
sub-Saharan Africa and the poorest countries one of its main priorities. 
 
According to the Government Accountability Office (G A O), $1 trillion was saved by the 
US health care system from 1999 to 2010 through generic substitution. Examining 
generic medications that have entered the market since 2001, the Generic Pharmaceutical 
Association reported a total cost savings of more than $360 billion by the end of 2010. 
Patent settlements also contributed to cost savings, because 16 of th22generic drugs that 
came out in 2011 were launched prior to patent ex. 
                                                 
31 US Pharmaceutical Industry Report, 2008-2009, Available:  04/2009, P.117 
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China has become an attractive destination for those who are dealing with 
“pharmageddon.” Brand name companies and generic companies alike are seeking to 
expand to China due to the country’s growing economy. According to Nick Beckett, head 
of the life sciences industry group at CMS Cameron McKenna, 
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 “[China] is currently the 5th largest pharmaceutical market globally, predicted to become 
2nd by 2015.  GSK emerged very high in chine due to the fact that in this country generic 
brand are helping people to get to treatment and save money. Between 2007 and 2010, 
the generic market in China grew more than 25%  a year on average and is forecast to 
grow about 14% a year in the coming few years.” 
The generic companies have much to gain due to the series of patent expirations that 
began some years ago. Generic drugs increasingly are being favoured as a result of health 
care cost containment. While crisis slows operations in most areas of generics drugs, the 
pharmaceutical industry against GSK takes the foot. It is the turn of GlaxoSmithKline 
(GSK) to be passed to the offensive. The pharmaceutical company has formalized the 
acquisition of Stiefel for U.S. $ 3.6 billion (2.8 billion euros). 
 
Certainly, it is less compared to its evolution as GSK alliance with Aspen generics for 
drugs, but it will allow GSK to triple its turnover to the tune of $ 1.5 billion, the very 
promising segment of dermatology. Besides the portfolio GSK has several products in 
development. 
 
In fact, in this race to the size engage large laboratories, two strategies compete. 
- There are those who proceed through mega-mergers (Pfizer, Roche, Merck). 
- There are also those who prefer to opt for more targeted acquisitions: GSK and Sanofi-
Aventis is giant French generics medications fall into this framework.32 
 
The pharmaceutical industry has beautifully showed strong profitability, especially 
compared to other sectors; it is not only the health that justifies all these movements. 
Despite the competition from generics, many laboratories have no alternative to a merger 
or an extension of scope. They face patent expiry of blockbuster drugs (for a decline in 
activity in the range of $ 100 billion in the next few years and the rise of generics. 
Numerous drug companies have taken strides to reduce margins now with one eye on 
future growth by downsizing, merging with and acquiring other companies domestically 
                                                 
32 Frédéric St-Martin, GlaxoSmithKline: encouraging progress towards universal access to medicines. 
Health and education for all, Article. (Available: 25/02/ 2009) 
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and internationally, and focusing on biosimilars. As participants in these trends, generic 
companies should be well positioned to rise to the challenges presented by economic 
demands and manufacturing opportunities. All of these factors, along with China’s latest 
patent change and growing drug market, mean that the future of the generic 
pharmaceutical market in the United States will undoubtedly be complex and exciting.33 
GSK announced the price reduction of all drugs in the poorest countries in the world, 
which means that the company has finally settled on the side of Oxfam (pharmaceutical 
company) and agrees that all diseases are in developing countries and we expect now is 
to see GSK to extend its offer to all developing countries and not to prevent generic 
alternatives to offer even cheaper in poorer countries, where reductions GSK are not 
sufficient. We will continue to encourage GSK to go through.34 
 
 Negative changes: 
Generic medications, subject to the production foul concurrency in highly regulated 
markets generic drugs provided not escape the laws of the market and the competition 
between the companies operating these drugs. 
GSK also found negative changes because of regulations made by judges articulation 
between the competition rules and the objective of ensuring a high level of health and 
human protection, GSK will also follow a case-by-case regulation national and 
international their effects on the free movement of goods as well as their need with regard 
to the protection of public health highly regulated and losing more time than expected to 
GSK in its deliveries. 
Generics do not escape the laws of the market. This is why GSK is found in many 
political and financial difficulties. 
GSK announced that it would establish a patent for research on neglected diseases. These 
neglected diseases are not publicized. A patent pool is an agreement between two parties 
to one or more of their patents available "in community", allowing any third party to use. 
                                                 
33 Frédéric St-Martin, GlaxoSmithKline: encouraging progress towards universal access to medicines. 
Health and education for all, Article. (Available: 25/02/ 2009) 
 
34 Ibid 
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A patent allows researchers to bypass the mountain patent that prevents them from 
sharing their knowledge and use of others to find new ways to develop new vaccines or 
drugs. It can also improve access to existing drugs.35 
  
It is exciting that GSK has accepted the concept of a patent because it has a deep meaning 
for many people. However, unless GSK and other companies make greater efforts to 
expand the concept of community patent to include treatments against HIV and AIDS and 
use it to improve access to medicines and not only innovation, we will not achieve our 
goal of universal access to medicines. 
Moreover, as these laboratories recorded a decline in the productivity of their search, they 
have few alternatives available to them. 
 
The phenomenon of concentration, however, should serve to provide greater resources for 
research.  
As for the diversification of the product portfolio is a parade that should be more popular. 
GlaxoSmithKline wants to sell drugs cheaper in poor countries. He challenged his 
competitors to do the same. 
 
GSK will reduce drug prices in 50 poorest countries in the world. The invoice will be 
raised to a level not exceeding 25% of the rates charged in the United Kingdom and the 
United States, less if possible. 
This is the new CEO of GSK, Andrew Witty, who made the announcement, revealing the 
outlines of his new strategy in least developed countries to its promotion. 
The boss of world number two pharmaceutical industry has challenged its competitors to 
follow his example. 
In addition to the revision of tariffs, the new strategy also relies on the sharing of 
knowledge protected by patents and important research on rare diseases. 
 
Despite the efforts of GSK, difficult access to patents deprive poor countries of more 
                                                 
35 http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-Annual-Report-2011.pdf  ( Available: 
17/11/2012) 
 
40 
 
generic drugs and cheaper. 
 
In addition, the CEO of GSK stated that 20% of the profits made by the group in the least 
developed countries will be reinvested in health system hospitals, clinics, medical 
personnel 
and this will cause a large deficit GSK 
This situation of changes in GSK coincides with a less than favourable global economic 
outlook, which has driven patients and drug developers to look for ways to cut costs. 
Pharmaceutical companies, and particularly the ones that market the brand name drugs 
going off patent, have been anticipating this event for several years. Some have 
undergone restructuring to cut costs and offset their market losses. These actions have 
resulted in a lot of lost jobs in the industry within the past years as well as company 
mergers and acquisitions that have increasingly gone abroad. In addition, 
GlaxoSmithKline has investing in innovation with the hope of a brighter future, with 
many focused on specialty pharmaceuticals. Sales and profits at GlaxoSmithKline, 
Europe's largest drug maker, have been hit by austerity measures in Europe and price cuts 
in some emerging markets, along with unrest in the Middle East.36 
 
The group's first-quarter results missed analysts' expectations, and sent its shares down 
3.1%.GSK said that the price reductions imposed by cash-strapped European 
governments as part of cutbacks in healthcare spending were bigger than expected and 
would probably average between 4% and 5% for the rest of the year. 
Russia and Turkey have also cut spending. Political upheaval in the Middle East, where 
GSK is the market leader, has also dented sales, as has a mild flu season on winter.   
GSK has been reducing the group's reliance on what he calls "white pills in western 
markets", which are particularly vulnerable to price cuts and competition from generic 
drug makers. Sales in Europe, and the Middle East and Africa of GSK, dropped by 6%, 
                                                 
36 GSK generate responsibility report 2003.p.32 
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but Witty was confident sales from emerging markets would soon return to the more 
normal growth rate of 11% or more.37 
Turnover and core operating profits grew by 1% between January and March, with core 
earnings per share up 5% at 27.3p. Quarterly sales of £6.6bn fell short of City 
expectations of £6.8bn; Net profits were down 13% to £1.3bn. 
The company is largely over the "patent cliff" – a trough caused by patent expiration on 
big-selling drugs – though there is uncertainty over when the lung drug Advair, one of 
GSK's best sellers, will face generic competition. It also unclear whether the follow-on 
medicine, Relovair, which showed mixed results in clinical trials, can plug the gap. Witty 
said the drug maker had received positive data for five products in late-stage 
development to treat HIV, cancer, diabetes and asthma. 
GSK's late-stage pipeline has been slowly improving, overall, a mixed quarter, yet the 
long-term growth with GSK continues to look comparatively bad. 
 
The pharmaceutical company is also trying to replenish its drug portfolio by buying in 
medicines. GSK pounced on its long-term partner Human Genome Sciences with a 
$2.6bn (£1.6bn) offer, which was swiftly rebuffed by the Maryland-based biotech firm.38 
The acquisition of the agreement would give the GSK company full ownership and the 
right to the first new treatment for lupus in half a century and Human Genome's only 
product on the market, as well as experimental diabetes and heart treatments. GSK still 
finds a way to improve and target customer in all medication market. 
 
 
  
 
 
 
 
 
                                                 
37 http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-Annual-Report-2011.pdf  
 ( Avalailable: 01/12/2012) 
38 http://www.guardian.co.uk/business/2012/apr/25/glaxosmithkline-shares-slide-first-quarter 
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Conclusion 
 
  
Despite the dominance of the pharmaceutical markets in the world, GSK has continued 
the strategy of development world based on production to increase their international 
sales as the research development. Although it is known that GSK inconvenient by 
decrease in sales, the company has also taken a leap forward after its decision to generics 
products and had an increase, thanks to the sale of generics medicines in poor countries 
and countries where the cost of the drug are very high and are not reimbursed by the 
government like in the US. 
GlaxoSmithKline's diversification strategy was to maintain its position in the emerging 
market and to get access to a broad range of low-cost branded but unpatented drugs. 
Although GSK took a breakthrough entry into the emerging market for branded generics 
it face a lot of challenges Intellectual property (IP) exposure and drug pricing controls.39 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
39 http://www.ukessays.com/essays/marketing/glaxosmithklines-diversification-strategy-and-market-
analysis-marketing-essay.php#ixzz2D2aqPyCV ( Available: 23/11/2012) 
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Afterthoughts 
 
  
The main aim of this project was to look into how a company as GSK, known for 
patented drugs has successfully entered in the generic market. Initially, we were going to 
look into what success drivers were employed in the transformation from patent drugs to 
generic drugs. Although, it will be interesting to know the success drivers, we could not 
generate any concrete problem to work with within this area. This led us to focus on one 
success driver, which is the brand positioning, which we believe have played a major role 
in the shifting. 
So in this chapter, we will focus on giving account on the limitations this project has been 
exposed to. 
The major, limitations are time and resources and financial limitations, because if we had 
more time, we could have looked into other success drivers such as the company's 
marketing strategies and how they have all contributed in the shifting from patent to 
generic drugs. 
Also, conducting a meeting with the marketing manager of GSK, London, would have 
giving us a more detailed information about the shifting process and not just the 
information found on their webpage. 
If we had had much time, we could also have conducted a semi structured interview of 
the population to discover the perception customers have of GSK. And also, it would be 
interesting to know the place GSK occupies in the minds of its consumers. 
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